223
The production process of mRNA drugs is lengthy, and rapid evaluation of the effect of drug targets in cells and even in vivo in small batches is of great significance for lowering the threshold of early research of mRNA drugs.
On June 5, Dr. Lyong Li, Director of Nucleic Acid Drug R & D Department (the first from right), was invited for the participation of the 6th VacCon 2024 Research and Development and Industrialization Forum of New Vaccines and nucleic acid Therapy, and shared the theme report of "Lightweight mRNA Drug Early Research Process Plan" in the "Nucleic Acid Vaccine and Therapy" special forum.
Hzymes greatly simplifies the scientific research grade mRNA/LNP production process, meets the extreme requirements of early research customers for speed and cost, realizes "zero threshold" into the mRNA platform, and jointly contributes wisdom and strength to the sustainable development of the industry.
In view of the traditional LNP's unstable and complicated sore points, Hzymes have developed a ready-to-use delivery scheme.
This ready-to-use LNP encapsulation scheme is specially developed for in-vivo RNA delivery in experimental animals. It is widely applicable to various RNA types such as mRNA, gRNA, saRNA and circRNA by utilizing the unique in-vivo transport and transmembrane delivery mechanism of LNP technology.
1. Ready-to-use, simple mixing and no sample loss, mRNA as low as 1 μg can also be directly encapsulated for in vivo experiments
2. No pack equipment required, saving equipment and labor costs
3. Exclusive lipids and formulations, no patent conflicts with moderna and BNT/ Pfizer LNP formulations
4. Rapid in vivo screening, direct expression verification at animal level, one step in place, shorten the screening verification cycle
5. High biosafety, ethanol free
Long Press to Scan QR Code
Scan QR Code
